Sugammadex Is Not a Silver Bullet: Caveats Regarding Unmonitored Reversal

Michael M. Todd, Aaron F. Kopman

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
Issue number1
StatePublished - Jul 1 2023

Bibliographical note

Funding Information:
Dr. Todd has been an unpaid and unreimbursed consultant to several manufacturers of neuromuscular blockade monitoring equipment. Dr. Kopman is not supported by, nor maintains any financial interest in, any commercial activity that may be associated with the topic of this article.

PubMed: MeSH publication types

  • Editorial
  • Comment

Cite this